HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Roxithromycin

Subscribe to New Research on Roxithromycin

Semisynthetic derivative of erythromycin. It is concentrated by human phagocytes and is bioactive intracellularly. While the drug is active against a wide spectrum of pathogens, it is particularly effective in the treatment of respiratory and genital tract infections.

Also Known As:

1A Brand of Roxithromycin; Alpharma Brand of Roxithromycin; Aventis Brand of Roxithromycin; Basics Brand of Roxithromycin; Biaxsig; Claramid; Faes Brand of Roxithromycin; Grünenthal Brand of Roxithromycin; Hexal Brand of Roxithromycin; Hoechst Brand of Roxithromycin; Infectopharm Brand of Roxithromycin; Infectoroxit; Juta Brand of Roxithromycin; Knoll Brand of Roxithromycin; Lichtenstein Brand of Roxithromycin; MIP Brand of Roxithromycin; MTW Brand of Roxithromycin; MTW-Roxithromycin; Macrosil; Medeva Brand of Roxithromycin; Merck dura Brand of Roxithromycin; Pfizer Brand of Roxithromycin; RU 28965; RU 965; RU-28965; RU-965; Rotesan; Rotramin; Roxi 1A Pharma; Roxi Basics; Roxi TAD; Roxi-Puren; Roxi-Q; Roxi-Wolff; Roxi-paed 1A Pharma; Roxi-saar; Roxibeta; Roxigamma; Roxigrün; Roxihexal; Roxithro-Lich; Rulid; Rulide; Sigma Brand of Roxithromycin; TAD Brand of Roxithromycin; Wolff Brand of Roxithromycin; Wörwag Brand of Roxithromycin; betapharm Brand of Roxithromycin; ct-Arzneimittel Brand of Roxithromycin; roxi von ct; roxidura; RU28965; RU965; Roxithromycin Hexal Brand; Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime), (9E)-

Networked: 324 relevant articles (55 outcomes, 85 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Oyama, Tohru: 3 articles (06/2009 - 01/2005)
2.	Suzaki, H: 3 articles (05/2004 - 02/2001)
3.	Hisamitsu, T: 3 articles (05/2004 - 02/2001)
4.	Asano, K: 3 articles (05/2004 - 02/2001)
5.	Horio, T: 3 articles (01/2002 - 11/2001)
6.	Akamatsu, H: 3 articles (01/2002 - 11/2001)
7.	Lindholt, Jes S: 2 articles (10/2009 - 12/2002)
8.	Sakuta, Tetsuya: 2 articles (06/2009 - 01/2005)
9.	Yamazaki, Soji: 2 articles (09/2008 - 01/2006)
10.	Hatamochi, Atsushi: 2 articles (09/2008 - 01/2006)

Related Diseases

1.	Infection 08/01/1992 - "burgdorferi infection was established in gerbils; a dosage of greater than or equal to 25 mg/kg/day roxithromycin for 10 days eliminated the infection. " 11/01/1987 - "Roxithromycin should be considered as an effective and safe oral antibiotic to treat children with upper and lower respiratory tract and skin infections due to common pathogens." 04/01/1991 - "The clinical efficacy of a macrolide antibiotic, roxithromycin, was evaluated in 24 patients affected by acute odontogenic infections. " 04/01/1991 - "[The clinical efficacy of roxithromycin in patients with acute odontogenic infections]" 12/01/1992 - "To evaluate the clinical efficacy and tolerance of roxithromycin in the treatment of odontogenic infections, an open study was performed. " Order ALL the reference details at left...
2.	Respiratory Tract Infections (Respiratory Tract Infection) 05/01/1992 - "The results indicate that both drugs are equally effective in the treatment of respiratory tract infection, but that roxithromycin is better tolerated." 05/01/1992 - "These results, allied with its improved pharmacokinetic properties, suggest that roxithromycin should be an effective treatment in children and adults for upper and lower respiratory tract infections caused by M. " 06/01/1991 - "[Efficacy of roxithromycin in the treatment of lower respiratory tract infections in patients with chronic respiratory disease]" 06/01/1998 - "A new paediatric formulation of roxithromycin was tested for acceptability, efficacy and safety in a multicentre, prospective, non-comparative trial in 210 children, aged between 2 and 8 years, with a variety of respiratory tract infections. " 04/01/1996 - "The study suggests that roxithromycin is an effective and well tolerated antibacterial in the treatment of lower respiratory tract infection." Order ALL the reference details at left...
3.	Sinusitis 03/01/1998 - "Roxithromycin thus appears to be an effective and well-tolerated drug for the treatment of acute and recurrent sinusitis." 02/01/1997 - "We studied the clinical efficacy of roxithromycin (RXM) administered at the daily dosage of one tablet (150 mg) for 3 months in 30 patients with chronic sinusitis. " 04/01/2009 - "[An empirical study of treating chronic sinusitis with low dose Roxithromycin]" 04/01/2009 - "CONCLUSION: Low dose Roxithromycin has good long term curative effect in treating chronic sinusitis. " 04/01/2009 - "OBJECTIVE: Observe the therapeutic effect of low dose Roxithromycin in treating chronic sinusitis and further discuss the mechanism of Roxithromycin facil endothelial cell apoptosis. " Order ALL the reference details at left...
4.	Asthma (Bronchial Asthma) 09/01/2005 - "BACKGROUND: Roxithromycin (RXM), a new 14-member macrolide antibiotic, is effective for chronic airway diseases such as diffuse panbronchiolitis and bronchial asthma. " 08/08/2003 - "A new macrolide, roxithromycin, may be an effective treatment for asthma. " 06/01/2004 - "[Effects of roxithromycin on a guinea pig model for chronic asthma]" 08/08/2003 - "Lymphocyte apoptosis was evaluated by incubating cells from patients with asthma in the presence of roxithromycin. " 08/08/2003 - "Roxithromycin promotes lymphocyte apoptosis in Dermatophagoides-sensitive asthma patients." Order ALL the reference details at left...
5.	Acne Vulgaris 01/01/2004 - "We clinically evaluated roxithromycin (ROM) in a double blind, placebo-controlled, and crossover trial in patients with inflammatory acne. " 01/01/2004 - "Clinical evaluation of roxithromycin: a double-blind, placebo-controlled and crossover trial in patients with acne vulgaris." 01/01/1998 - "[Treatment of acne by using roxithromycin and a study of the mechanism of the drug action]" 07/01/2009 - "Roxithromycin has a therapeutic effect on inflammatory acne and leads to improvement of quality of life in the patients." 07/01/2009 - "Effects of oral antibiotic roxithromycin on quality of life in acne patients." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Erythromycin (Erycette)
2.	Clarithromycin (Biaxin)
3.	Roxithromycin
4.	Azithromycin (Zithromax)
5.	Macrolides
6.	Anti-Bacterial Agents (Antibiotics)
7.	Sulfamethoxazole
8.	Ciprofloxacin (Cipro)
9.	Amoxicillin-Potassium Clavulanate Combination (Co-amoxiclav)
10.	Doxycycline (Vibramycin)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Drug Therapy (Chemotherapy)
3.	Stents
4.	Transplantation (Transplant Recipients)
5.	Immunomodulation

blog comments powered by Disqus

TREATMENT OPTIONS
for Infection,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 14555 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>